Search Medical Condition
Please enter condition
Please choose location from dropdown

South Burlington, Vermont Clinical Trials

A listing of South Burlington, Vermont clinical trials actively recruiting patient volunteers.

RESULTS

Found (155) clinical trials

A Registry for Patients With Chronic Hypoparathyroidism

This is a prospective, observational disease and drug registry designed to evaluate the safety and effectiveness profile of rhPTH(1-84) under conditions of routine clinical practice and to observe the clinical course of chronic hypoparathyrodism. No treatment is provided as a result of participating in this registry and all decisions on ...

Phase N/A

0.0 miles

Learn More »

A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab. The study population will consist of approximately 1050 male and female subjects aged 12 years who ...

Phase

0.94 miles

Learn More »

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.

Phase

0.94 miles

Learn More »

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. ...

Phase

0.94 miles

Learn More »

Efficacy and Safety of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU)

The purpose this study is to evaluate the efficacy, safety, and pharmacokinetics of GDC-0853 compared with placebo in participants with Chronic Spontaneous Urticaria (CSU) refractory to anti-histamines.

Phase

0.94 miles

Learn More »

QP ExCELs: MultiPole Pacing (MPP) Sub-Study

The objective of this MultiPole Pacing (MPP) sub-study of the QP ExCELs study is to demonstrate that the MPP feature is effective by converting a percentage of cardiac resynchronization therapy (CRT) non-responders to responders. The MPP sub-study is a single-arm, multi-center, prospective trial within the ongoing QP ExCELs study (NCT02290028).

Phase N/A

0.94 miles

Learn More »

A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy.

Phase

0.94 miles

Learn More »

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is ...

Phase

0.94 miles

Learn More »

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis

This is a multi-center, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.

Phase

0.94 miles

Learn More »

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

Duration per participant is until dupilumab approval for use in asthma and market availability to the patient, or a maximum of 144 weeks (ie, about 3 years) after the Start of Treatment (V1), whichever comes first.

Phase

0.94 miles

Learn More »